deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT00985205

The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury (RE-ENERGIZE)

Effects of Enteral Glutamine Supplementation on Mortality and Infectious Morbidity in Severely Burned Patients: a Multi-center Pilot Trial

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Burns
Interventions Enteral Glutamine Placebo
Updated 17 times since 2017 Last updated: Dec 9, 2021 Started: Dec 31, 2010 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00985205, this PHASE3 trial focuses on Burns and remains ongoing. Sponsored by Canadian Institutes of Health Research (CIHR), it has been updated 17 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshot~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jan 2024 · 24 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Jan 2024 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  5. Jan 2022 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 12 earlier versions

  1. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  3. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  5. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Jun 2019 — Jun 2020 [monthly]

    Recruiting PHASE3

  7. Sep 2018 — Jun 2019 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  9. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  10. Aug 2017 — Apr 2018 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Institutes of Health Research (CIHR)
  • Daren K. Heyland
Data source: Clinical Evaluation Research Unit at Kingston General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Akron, United States , Asunción, Paraguay , Augusta, United States , Aurora, United States , Bangkok, Thailand , Birmingham, United Kingdom , Bridgeport, United States , Calgary, Canada , Columbus, United States and 41 more locations